ERROR: Macro njDefaultArticleHeader is missing!

Grapevine

EDA’s emergency management

Back to Top Comments Email Print

Latest News

Corporate America Realty & Advisors leases Little Falls industrial site

By Elana Knopp
May 23, 2018 12:48 PM

Rutherford-based Corporate America Realty & Advisors President Howard Applebaum recently represented H.C. International Inc. in an industrial lease agreement in Little Falls. CONTINUE READING

Princeton-based drug researcher opens Tokyo office

By Vince Calio
May 22, 2018 11:17 AM

WIRB-Copernicus Group, a Princeton-based medical research group, has opened a Tokyo office to expand its capabilities in conducting global clinical trials. CONTINUE READING

advertisement

Advance Realty Executive Quarters at Bedminster wins TOBY award

By Elana Knopp
May 22, 2018 07:20 AM

Advance Realty Executive Quarters at Bedminster has been named The Outstanding Building of the Year by the New Jersey chapter of the Building Owners and Managers Association. CONTINUE READING

Marcus & Millichap completes sale of Union City mixed-use building

By Elana Knopp
May 22, 2018 01:01 PM

Marcus & Millichap recently wrapped up the sale of a mixed-use building in Union City for almost $1.8 million. CONTINUE READING

NAI Hanson negotiates sale of Elmwood Park industrial/flex facility

By Elana Knopp
May 22, 2018 11:47 AM

NAI James E. Hanson real estate firm has negotiated the sale of a 45,000-square-foot industrial/flex building in Elmwood Park. CONTINUE READING

Hackensack Performing Arts Center wins Historic Preservation Award

By Elana Knopp
May 22, 2018 11:22 AM

The DMR Architects-designed Hackensack Performing Arts Center recently received the 2018 Bergen County Historic Preservation Award for its adaptive reuse of the former Masonic Temple in downtown Hackensack. CONTINUE READING

Cohen Seglias expands New Jersey office

By Gabrielle Saulsbery
May 21, 2018 01:45 PM

Three attorneys had joined Cohen, Seglias, Pallas, Greenhall & Furman PC’s Newark office. CONTINUE READING

advertisement

With a long-delayed incentives overhaul on its way to becoming law, the state is rolling out emergency guidelines to open itself for business under the new programs, sources said.

One person said the Economic Development Authority could start accepting applications for the new incentives as soon as October, assuming Chris Christie signs the Economic Opportunity Act into law as expected. To do so, a source said, the agency is expected to adopt temporary regulations and formalize them at a later time.

The move would allow many firms and developers to break their holding patterns of the past several months, as they waited on lawmakers and administration officials who wrangled over the high-stakes bill. But the lengthy delay also has allowed the EDA to prepare for a wave of applications, a source said.

The person said the normal process of adopting regulations “just takes time, and there would be a significant void if they went with that process,” because big-ticket incentives like the Urban Transit Hub and Grow New Jersey tax credits are running on empty.

Sale of Ortho sensible for J&J

Speculation has resurfaced that Johnson & Johnson is looking sell its blood-test division, Ortho Clinical Diagnostics, by the end of the year.

Sources following the pharma industry say such a move make sense because blood tests tend to be a low-tech, lower-margin business, offering less returns than newer categories of tests, such as molecular diagnostics, which examine genes.

“This is not a high-margin business,” one source said of blood tests. “It does not add to return on investment. Why do low ROI? It makes no sense. Twenty years ago, you could, because no one else was doing it. But now smaller companies are doing it at lower cost.”

The Wall Street Journal has reported J&J is talking to other health care companies and private equity investors. The New Brunswick-based company isn't talking now, though CEO Alex Gorsky in January said the company was considering divesting the asset as it  focuses more on higher growth drivers. 

Gorsky has said the blood-testing unit may be a better fit as part of another company, or as a standalone company.

Grapevine reports on the behind-the-scenes buzz in the business community. Contact Editor Tom Bergeron at tomb@njbiz.com.

Share This Story On:

EDA’s emergency management

Back to Top Comments Email Print

Latest News

advertisement

With a long-delayed incentives overhaul on its way to becoming law, the state is rolling out emergency guidelines to open itself for business under the new programs, sources said.

One person said the Economic Development Authority could start accepting applications for the new incentives as soon as October, assuming Chris Christie signs the Economic Opportunity Act into law as expected. To do so, a source said, the agency is expected to adopt temporary regulations and formalize them at a later time.

The move would allow many firms and developers to break their holding patterns of the past several months, as they waited on lawmakers and administration officials who wrangled over the high-stakes bill. But the lengthy delay also has allowed the EDA to prepare for a wave of applications, a source said.

The person said the normal process of adopting regulations “just takes time, and there would be a significant void if they went with that process,” because big-ticket incentives like the Urban Transit Hub and Grow New Jersey tax credits are running on empty.

Sale of Ortho sensible for J&J

Speculation has resurfaced that Johnson & Johnson is looking sell its blood-test division, Ortho Clinical Diagnostics, by the end of the year.

Sources following the pharma industry say such a move make sense because blood tests tend to be a low-tech, lower-margin business, offering less returns than newer categories of tests, such as molecular diagnostics, which examine genes.

“This is not a high-margin business,” one source said of blood tests. “It does not add to return on investment. Why do low ROI? It makes no sense. Twenty years ago, you could, because no one else was doing it. But now smaller companies are doing it at lower cost.”

The Wall Street Journal has reported J&J is talking to other health care companies and private equity investors. The New Brunswick-based company isn't talking now, though CEO Alex Gorsky in January said the company was considering divesting the asset as it  focuses more on higher growth drivers. 

Gorsky has said the blood-testing unit may be a better fit as part of another company, or as a standalone company.

Grapevine reports on the behind-the-scenes buzz in the business community. Contact Editor Tom Bergeron at tomb@njbiz.com.

Share This Story On:
advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy
advertisement
ERROR: Macro defaultSidebar is missing!
ERROR: Macro footer_top is missing!
Back to Top